首页> 美国卫生研究院文献>Aging (Albany NY) >A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt/β-catenin signaling via interacting with TET1 and miR-888
【2h】

A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt/β-catenin signaling via interacting with TET1 and miR-888

机译:来自APC的环状RNA通过与TET1和miR-888相互作用而失活Wnt /β-catenin信号传导从而抑制了弥漫性大B细胞淋巴瘤的增殖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Circular RNA (circRNA), a type of non-coding RNA, can promote or suppress tumorigenesis. To investigate the involvement of circRNA in diffuse large B-cell lymphoma (DLBCL), we performed a circRNA microarray analysis on paired DLBCL and normal tissues. We identified a novel and highly stable circRNA originating from the back-splicing of APC exon 7 to exon 14, circ-APC (hsa_circ_0127621), which was downregulated in DLBCL tissues, cell lines and plasma. In gain-of-function experiments, ectopic expression of circ-APC inhibited DLBCL cell proliferation in vitro and tumor growth in vivo. Cytoplasmic circ-APC functioned as a sponge for miR-888, thus post-transcriptionally upregulating APC by alleviating the repressive effects of miR-888 on this gene. Further, nuclear circ-APC bound to the APC promoter and recruited the DNA demethylase TET1, thereby transcriptionally upregulating APC. Upon its upregulation, APC dampened the canonical Wnt/β-catenin signaling pathway by reducing the accumulation of β-catenin in the nucleus, thereby retarding DLBCL growth. Clinically, circ-APC was found to be an effective diagnostic and prognostic biomarker for patients with DLBCL. Our study suggests that circ-APC is a novel proliferation inhibitor, and that restoring circ-APC expression may be a promising therapeutic approach for DLBCL patients.
机译:环状RNA(circRNA)是一种非编码RNA,可以促进或抑制肿瘤发生。为了调查circRNA在弥漫性大B细胞淋巴瘤(DLBCL)中的参与,我们对配对的DLBCL和正常组织进行了circRNA微阵列分析。我们鉴定了一种新颖且高度稳定的circRNA,其源于APC外显子7向外显子14的反向剪接,即circ-APC(hsa_circ_0127621),其在DLBCL组织,细胞系和血浆中被下调。在功能获得性实验中,circ-APC的异位表达在体外抑制DLBCL细胞增殖,在体内抑制肿瘤生长。细胞质circ-APC充当miR-888的海绵,因此通过减轻miR-888对该基因的抑制作用,在转录后上调APC。此外,核circ-APC与APC启动子结合并募集DNA脱甲基酶TET1,从而转录上调APC。在其上调后,APC通过减少细胞核中β-catenin的积累,从而抑制了DLBCL的生长,从而抑制了经典的Wnt /β-catenin信号传导途径。在临床上,发现circ-APC是DLBCL患者的有效诊断和预后生物标志物。我们的研究表明,circ-APC是一种新型的增殖抑制剂,恢复circ-APC的表达对于DLBCL患者可能是一种有前途的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号